ライフサイエンスコーパス: contralateral breast cancer

1 and cumulative risks of breast, ovarian, and contralateral breast cancer.

2 rrence of invasive locoregional, distant, or contralateral breast cancer.

3 ugh few had a clinically significant risk of contralateral breast cancer.

4 lower risks of breast cancer recurrence and contralateral breast cancer.

5 free survival, overall survival, and time to contralateral breast cancer.

6 -fold (95% CI, 1.9 to 26.5) elevated risk of contralateral breast cancer.

7 ld (95% CI, 1.03-19.0) increased risk of ER- contralateral breast cancer.

8 y higher risk of developing a second primary contralateral breast cancer.

9 d the absolute occurrence of ipsilateral and contralateral breast cancer.

10 e a substantially reduced risk of developing contralateral breast cancer.

11 ifen might play in the reduction of risk for contralateral breast cancer.

12 ed as potential risk factors for synchronous contralateral breast cancer.

13 Eight women developed a contralateral breast cancer.

14 r carcinoma in situ (LCIS) were followed for contralateral breast cancer.

15 .22-0.63; p<0.0001), but having no effect on contralateral breast cancer (0.84, 0.45-1.58; p=0.6).

16 for disease recurrence or the occurrence of contralateral breast cancer, 0.66; P=0.01 by a two-sided

17 Among the 704 participants with contralateral breast cancer, 108 (15.3%) were identified

18 ed 5 years reduces the risk of recurrence or contralateral breast cancer 15 years after starting trea

19 es (324 vs 375, 0.86, 0.74-0.99, p=0.04) and contralateral breast cancers (35 vs 59, 42% reduction, 1

20 tases (89% v 92%, respectively; P = .16), or contralateral breast cancer (6% v 6%, respectively; P =

21 ving disease recurrence or the occurrence of contralateral breast cancer (67 with letrozole and 98 wi

22 ated that desires to decrease their risk for contralateral breast cancer (98%) and improve survival (

23 vivors had an increased risk of metachronous contralateral breast cancer (adjusted hazard ratio [HR],

24 Information is limited on the risk of contralateral breast cancer after a diagnosis of breast

25 the hazard ratio (HR) for the occurrence of contralateral breast cancer after CPM was 0.03 (95% CI,

26 d smoking on risk of second primary invasive contralateral breast cancer among breast cancer survivor

27 47 years; IQR, 40-55 years) eligible for the contralateral breast cancer analysis, 426 were diagnosed

28 ve invasive breast cancer and second primary contralateral breast cancer and 728 matched control wome

29 ated breast cancer are at increased risk for contralateral breast cancer and ovarian cancer and there

30 Probabilities for developing contralateral breast cancer and ovarian cancer, dying fr

31 Aromatase inhibitors prevent more contralateral breast cancers and cause fewer side effect

32 seems to protect against the development of contralateral breast cancer, and although women who unde

33 The risks of subsequent contralateral breast cancer are substantial for women wh

34 This study assessed the risk of subsequent contralateral breast cancer associated with carrying a B

35 ns were significantly more likely to develop contralateral breast cancer at 5 years (31% v 4%, P=.000

36 rolled in the trial who did not have a known contralateral breast cancer at the time of surgical plan

37 Given these patients' high risk for contralateral breast cancer, bilateral mastectomy is inc

38 reast cancer survivors at risk of developing contralateral breast cancer (CBC) is increasing.

39 Contralateral breast cancer (CBC) is the most frequent n

40 ersus routine surveillance as an alternative contralateral breast cancer (CBC) risk management strate

41 Rates of IBTR, distant recurrence, and contralateral breast cancer (CBC) were among the end poi

42 er diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC).

43 er diagnosis, roughly 5% of patients develop contralateral breast cancer (CBC).

44 tify factors predictive of HRL and/or occult contralateral breast cancer (CBC).

45 fy genetic and environmental determinants of contralateral breast cancer (CBC).

46 netic resonance imaging (MRI) detects occult contralateral breast cancers (CBCs) in women with breast

47 tes of in-breast tumor recurrence (IBTR) and contralateral breast cancers (CBCs).

48 ation Epidemiology [WECARE]) of asynchronous contralateral breast cancer conducted during the period

49 ancer and are judged to be at high risk of a contralateral breast cancer, contralateral risk-reducing

50 Contralateral breast cancer developed in 0.5% of women w

51 Contralateral breast cancer developed in 2.7% of women w

52 his nested case-control study, patients with contralateral breast cancer diagnosed 1 year or more aft

53 ancer, 109 with ovarian cancer, and 245 with contralateral breast cancer during follow-up.

54 and 10-year cumulative) risks of developing contralateral breast cancer following a first invasive b

55 The relative risk of contralateral breast cancer for BRCA1 mutation carriers

56 e age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to

57 essed the long-term risks of ipsilateral and contralateral breast cancer in a cohort of young women w

58 tion is available on the subsequent risks of contralateral breast cancer in mutation carriers.

59 The annual incidence rate of contralateral breast cancer in the letrozole group was 0

60 mary endpoints were rates of ipsilateral and contralateral breast cancer, in relation to germline BRC

61 al prophylactic mastectomy (CPM) in reducing contralateral breast cancer incidence and breast cancer

62 silateral breast tumour recurrence rates and contralateral breast cancer incidence are scarce, but to

63 (local, regional, or distant recurrence, or contralateral breast cancer, invasive disease, or ductal

64 In particular, the risk of a contralateral breast cancer is reviewed to help guide th

65 sk of the relatively uncommon outcome of ER- contralateral breast cancer may now need to be tallied a

66 isk of hormone receptor-specific subtypes of contralateral breast cancer (n = 303 ER+ and n = 52 ER-

67 oking were all positively related to risk of contralateral breast cancer (odds ratio [OR], 1.4; 95% C

68 en for >or=5 years had a reduced risk of ER+ contralateral breast cancer [odds ratio, 0.4; 95% confid

69 ory of HRT did not have an increased risk of contralateral breast cancer or second non-breast cancer

70 Participants previously diagnosed with contralateral breast cancer or unilateral breast cancer

71 in regional recurrence, distant metastases, contralateral breast cancers, or new breast cancers were

72 time to distant recurrence, incidence of new contralateral breast cancer, overall survival, and death

73 regimens, a significant excess incidence of contralateral breast cancer (rate ratio 1.18, SE 0.06, 2

74 Contralateral breast cancer rates are declining as well

75 95% CI, 2.0- to 5.8-fold) increased risks of contralateral breast cancer, respectively.

76 Contralateral breast cancer risk decreased significantly

77 sed on promising data involving reduction of contralateral breast cancer risk in adjuvant studies, se

78 women with low-penetrance mutations (assumed contralateral breast cancer risk of 24% and ovarian canc

79 hose with high-penetrance mutations (assumed contralateral breast cancer risk of 65% and ovarian canc

80 , smoking, and alcohol consumption influence contralateral breast cancer risk, affording breast cance

81 een these three exposures and second primary contralateral breast cancer risk.

82 use for <5 years was not associated with ER- contralateral breast cancer risk.

83 ts, the current evidence for ipsilateral and contralateral breast cancer risks in older survivors of

84 The incidence of contralateral breast cancer seems to be reduced signific

85 ast examination and mammography in detecting contralateral breast cancer soon after the initial diagn

86 sease-free survival and a lower incidence of contralateral breast cancer than those with placebo, but

87 For contralateral breast cancer, the cumulative risk 20 year

88 a trend toward higher risk for relatives of contralateral breast cancer vs unilateral breast cancer

89 r who underwent breast MR imaging at which a contralateral breast cancer was not identified, patient

90 arly dependent on TN status, but the risk of contralateral breast cancer was not.

91 The risk of contralateral breast cancer was significantly reduced (h

92 e corresponding risks of any recurrence or a contralateral breast cancer were 17%, 22%, and 26%, resp

93 For the 357 postmenopausal women, 50.3 contralateral breast cancers were predicted, whereas onl

94 ers more accurately perceived their risk for contralateral breast cancer, whereas women without a kno

95 Life-tables for contralateral breast cancers, which consider age at firs

96 even patients were diagnosed with subsequent contralateral breast cancer, yielding 5- and 10-year act